<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970238</url>
  </required_header>
  <id_info>
    <org_study_id>2021PS522K</org_study_id>
    <nct_id>NCT04970238</nct_id>
  </id_info>
  <brief_title>Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction</brief_title>
  <official_title>Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction-- Multicenter Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhijun Sun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reperfusion therapy for acute ST segment elevation myocardial infarction (STEMI) can&#xD;
      significantly reduce mortality, but patients may still have heart failure and adverse&#xD;
      cardiovascular events due to massive myocardial loss. About 20% of patients present with&#xD;
      acute heart failure (AHF) at admission, It is the most important cause of hospital death in&#xD;
      acute myocardial infarction. Because of the large necrotic area of acute anterior myocardial&#xD;
      infarction, heart failure still occurs in a considerable number of patients even after&#xD;
      revascularization (PCI). Myocardial protection of ischemic myocardium is a hot topic in&#xD;
      clinical research.&#xD;
&#xD;
      Both ESC and Chinese heart failure guidelines recommend levosimendan for the treatment of&#xD;
      acute decompensated heart failure. A large number of studies have proved that levosimendan&#xD;
      can significantly reduce myocardial injury and improve cardiac function in patients with&#xD;
      acute STEMI complicated with left ventricular dysfunction and cardiogenic shock compared with&#xD;
      placebo. Basic research has confirmed that levosimendan can reduce the myocardial infarction&#xD;
      area after acute coronary occlusion, improve the left ventricular function, and exert the&#xD;
      effects of anti myocardial ischemia, myocardial injury, myocardial fibrosis, ventricular&#xD;
      remodeling and anti apoptosis. However, there is still a lack of early preventive application&#xD;
      of levosimendan in acute anterior myocardial infarction after PCI to improve ventricular&#xD;
      remodeling and reduce the incidence of heart failure.&#xD;
&#xD;
      The purpose of this study was to investigate the effect of early prophylactic levosimendan on&#xD;
      left ventricular remodeling, ischemic myocardial protection and the development of heart&#xD;
      failure in patients with acute anterior myocardial infarction after PCI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of heart failure</measure>
    <time_frame>6 month</time_frame>
    <description>6 month of heart failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>6 months</time_frame>
    <description>Mace is defined as cardiovascular death and cardiovascular related readmission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular systolic function</measure>
    <time_frame>72 hours</time_frame>
    <description>At 72 hours, left ventricular systolic function of AFI is as follows ( PSD, GLS, PSI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT-ProBNP</measure>
    <time_frame>30 days</time_frame>
    <description>Changes of NT-ProBNP at 72 hours and 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life score</measure>
    <time_frame>30 days</time_frame>
    <description>Seattle Angina Questionnaiire is used, The full score of five items in the scale is 100. The higher the score is, the better the condition is.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Levosimendan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Test drug: drug preparation method: 5ml (12.5mg) levosimendan injection was mixed with 500ml 5% glucose injection, the initial loading dose was 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg/ kg / min for 24 hours.</description>
    <arm_group_label>Levosimendan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Control drug: 5% glucose injection, intravenous injection method is the same as the experimental group pump dose, the initial load dose of treatment is 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg / kg / min for 24 hours.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age ≥ 18 years old.&#xD;
&#xD;
          -  2. Acute anterior wall myocardial infarction (ECG indicates acute anterior wall, acute&#xD;
             anterior wall myocardial infarction, acute extensive anterior wall myocardial&#xD;
             infarction).&#xD;
&#xD;
          -  3. The onset time of chest pain was less than 12 hours, and agreed to emergency PCI&#xD;
             treatment.&#xD;
&#xD;
          -  4. Be able to understand and sign informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients who cannot undergo PCI treatment after coronary angiography, or those who&#xD;
             fail to open blood vessels, or refuse to undergo PCI treatment.&#xD;
&#xD;
          -  2. Those whose coronary angiography results indicated myocardial infarction caused by&#xD;
             non-coronary artery disease or residual stenosis &lt; 50% after reanalization of&#xD;
             myocardial infarction without PCI treatment.&#xD;
&#xD;
          -  3. Patients with old anterior wall myocardial infarction.&#xD;
&#xD;
          -  4. Previous history of cardiac insufficiency.&#xD;
&#xD;
          -  5. Both anterior descending stent implantation, stent restenosis or stent thrombosis.&#xD;
&#xD;
          -  6. Symptomatic hypotension, systolic blood pressure &lt; 90mmHg (still &lt; 90mmHg with&#xD;
             IABP)&#xD;
&#xD;
          -  7, body temperature &gt; 38.5℃, or with serious infectious diseases (severe myocarditis,&#xD;
             severe pneumonia, severe urinary tract infection, etc.).&#xD;
&#xD;
          -  8. Severe other organ diseases (renal insufficiency: EGFR &lt; 30ml/min, severe liver&#xD;
             insufficiency, moderate and severe anemia, malignant tumor, hematologic system&#xD;
             diseases, etc.).&#xD;
&#xD;
          -  9. Known or suspected allergy to the active or inactive ingredients of the drug under&#xD;
             study.&#xD;
&#xD;
          -  10. Participated in other drug clinical trials within 3 months before the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shengjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Zhijun Sun</investigator_full_name>
    <investigator_title>Director of the second Department of cardiovascular medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Levosimendan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

